CYP3A7 is a member of the cytochrome P450 (CYP) 3A enzyme sub-family that is expressed in the fetus and neonate. In addition to its role… Read More »Characterization of fluorescent probe substrates to develop an efficient high-throughput assay for neonatal hepatic CYP3A7 inhibition screening
Hannah Work explains her CYP3A7 project at the ASPET Early Career Researcher presentations.
On September 20-22, 2021. Dr. LAMPE will present our research on drug metabolism in neonates.
Prophylactic antiretroviral therapy (ART) in HIV infected pregnant mothers and their newborns can dramatically reduce mother-to-child viral transmission and seroconversion in the neonate. The ritonavir-boosted… Read More »Inhibition of CYP3A7 DHEA-S Oxidation by Lopinavir and Ritonavir: An Alternative Mechanism for Adrenal Impairment in HIV Antiretroviral-Treated Neonates
On April 27-30, 2021. The LAMPE Lab will present several of their research works as poster or talk formats.
On February 22-26, 2021. Hannah WORK will present her work on developing a fluorescence-based high throughput assay for CYP3A7.
Polycyclic aromatic hydrocarbons (PAHs) are generated by the incomplete combustion of carbon. Exposures correlate with systemic immune dysfunction and overall immune suppression. Real-world exposures to… Read More »Comparing the effects of an exposure to a polycyclic aromatic hydrocarbon mixture versus individual polycyclic aromatic hydrocarbons during monocyte to macrophage differentiation: Mixture exposure results in altered immune metrics
On January 28, 2021. Dr Lampe presented a talk on Using LC-MS to identify CYP3A7 drug-hormone interactions and toxicity in the neonate.
